DAY 1 DAY 2 SESSION 1 Using New Technologies to Model Key
Total Page:16
File Type:pdf, Size:1020Kb
DAY 1 DAY 2 SESSION 1 Using new technologies to model key SESSION 2 SESSION 3 SESSION 4 questions in neurodegeneration Understanding and exploiting? – What do we want from disease models? Optimising future research Chair: Giampietro Schiavo differences in mouse and human Chair: Elizabeth Fisher Chair: Pietro Fratta Chair: Pietro Fratta Welcome by Royal Society & 09.00 Elizabeth Fisher Linda Greensmith Dorothee Dormann John Collinge Allan Bradley Mouse physiology and Cellular processes and The mouse toolbox we need for 09.10 Genomic humanisation and other 14.00 09.15 13.30 neuroanatomy in modelling neurodegenerative disease in mouse neurodegeneration - lessons from technologies in mouse neurodegenerative disorders models prion diseases Maria Grazia Spillantini Eric Karran Karen Duff Elizabeth Simpson Understanding neuropathology in What pharma needs, what biotech 09.40 14.30 09.45 Current challenges in 14.00 Viral models in neurodegeneration neurodegeneration models, needs, what we do right, what we neurodegeneration in mouse models aligning human and mouse do wrong? Ophir Shalem Gillian Bates 10.10 CRISPRs and neurodegeneration 15.00 Tea 10.15 Preclinical modelling 14.30 Tea models neurodegenerative disease in mouse Marco Tripodi Monica Justice 10.40 Coffee 15.40 Mouse neural circuits and 10.45 Coffee 15.00 Validity and reproducibility neurodegeneration models David Bannerman Takaomi Saido Mark Lythgoe Mouse modelling of human Susan Ackerman 11.20 Transgenics or knockins? The hare 16.10 11.15 15.30 Neuroimaging of mouse models behavioural changes in How we get to mechanism? or the tortoise? neurodegeneration Frances Wiseman Discussion (Pietro Fratta) Mark Good Working with complex mouse Differences in mouse versus Aligning mouse and human Discussion (Pietro 11.50 16.40 11.45 models to understand humans, are we simply modelling behaviours in neurodegeneration Fratta/Giampietro neurodegenerative disease mouse neurodegeneration? Schiavo/Elizabeth Fisher) 16.00 Differences in mouse versus Robert Burgess Discussion (Elizabeth Fisher) humans, are we simply modelling Analysing RNA metabolism in Transgenics or knock ins? Mouse mouse neurodegeneration? 12.20 12.15 mouse models of paradigms or translating into human neurodegeneration studies? Discussion (Giampietro Schiavo) 17.00 CLOSE 12.50 Tissue specificity, site of onset, time of onset, gain or loss of 12.30 LUNCH 17.00 CLOSE function 13.00 LUNCH .